Anxiety and Depression Treatment Market By Product (Antidepressant Drugs, SSRIs (Selective Serotonin Reuptake Inhibitor), SNRIs (Serotonin-Norepinephrine Reuptake Drug), Benzodiazepine, Devices and Therapy), By Indication (MDD (Major Depressive Disorder), OCD (Obsessive-Compulsive Disorder), Phobia), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2030

Report Code: PMI489922 | Publish Date: September 2022 | No. of Pages: 170

Anxiety And Depression Treatment Market Overview

Anxiety and depression disorders are a major cause of mental illness. Depression is more than just a feeling down or having a bad day.  When a sad mood lasts for a long time & interferes with normal, everyday functioning, you may be depressed. Feeling sad, irritated, anxious, experiencing headaches, pains, lack of sleep are the major symptoms of anxiety and depression. The factors that increase a persons chances of becoming depressed are: Going through a major life change, even if it was already planned, having severe disease like cancer, chronic pain or stroke. Experiencing traumatic or stressful events, such as physical or sexual abuse, death of loved one, or financial problems. Using alcohol or drugs

Globally, anxiety and depression has become the most increasing psychiatric disorder. Depression comorbid with anxiety has been associated with poorer health outcomes, including more severe symptoms & higher levels of suicidal ideation. Covid-19 has disrupted mental health services in most countries, WHO survey. Pandemic has increase the demand for mental health services which includes treatment and thus expected to increase in growth of target market. The global Anxiety and Depression Treatment market size accounted for US$ 10.89 billion in 2020 and is estimated to be US$ 13.85 billion by 2030 and is anticipated to register a CAGR of 2.7%.

Anxiety And Depression Treatment Market Dynamics

 

                                   Rise in mental illness and rate of newly medications

Rise in mental health illness of an individual is one of the leading factors for the global anxiety and depression treatment market growth. Moreover, increasing urban population is one of the driving factors for the global anxiety and depression treatment market. Urban culture affects the person’s living lifestyle. Living lonely causes the mental illness which requires development of treatment. The pandemic has driven the life of people much more harder and led to increase in anxiety and depression. However, the growth in research and development to overcome the mental illness in urban areas boosts the demand for target market.

                                                           Technological advancement

Technology has made a big impact on the treatment of chronic illnesses, such as major depression, because technology offers self-management strategies & significantly improves adherence to medications with reminders & messages of support. Digital care options through Teletherapy & all new apps have seen explosive growth during the pandemic.

Restrains:

Digital Technology helps depression sufferers who can’t take medicines. Increase in use of new Teletherapy and new apps has somewhat restrain the growth of target market.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Anxiety And Depression Treatment Market Segmentation

Source: Prophecy Market Insights

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

The global anxiety and depression treatment market is segmented based on product, indication, distribution channel, and region.

On the basis of product, the global anxiety and depression treatment market is segmented into Antidepressant drugs, SSRIs (Selective Serotonin Reuptake Inhibitor), SNRIs (Serotonin-Norepinephrine Reuptake Drug), Benzodiazepine, Devices and Therapy. On the basis of indication, the target market is segmented into MDD (Major Depressive Disorder), OCD (Obsessive-Compulsive Disorder), Phobia. On the basis of distribution channel the global anxiety and depression treatment market is classified into hospital pharmacy, retail pharmacy, and online pharmacy and others.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

On region the global anxiety and depression treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia-pacific market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as India and China, and technological advancements. Moreover, rising presence of industrial corridor is anticipated to increase demand for anxiety and depression treatment in the region.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020– 2030

Market representation

Revenue in USD Billion & CAGR from 2020 to 2030

Market Segmentation

By Product – Antidepressant Drugs, SSRIs (Selective Serotonin Reuptake Inhibitor), SNRIs (Serotonin Norepinephrine Reuptake Drug), Benzodiazepine, Devices and Therapy

By Indication – MDD (Major Depressive Disorder) , OCD (Obsessive-Compulsion Disorder), Phobia

By Distribution Channel – Hospital Pharmacy, Retail Pharmacy and Online Pharmacy

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the global anxiety and depression treatment report based on product, indication, distribution channel and region:

Global Anxiety and Depression Market, By Product:

  • Antidepressant Drugs
  • SSRIs (Selective Serotonin Reuptake Inhibitor)
  • SNRIs (Serotonin Norepinephrine Reuptake Drug)
  • Benzodiazepine
  • Devices
  • Therapy

Global Anxiety and Depression Market, By Indication:

  • MDD (Major Depressive Disorder)
  • OCD (Obsessive-Compulsive Disorder)
  • Phobia

Global Anxiety and Depression Market, By Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

 

Global Anxiety and Depression Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Anxiety And Depression Treatment Market Key Players

The key players operating the global anxiety and depression treatment market includes Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., AstraZeneca, Bristol-Myers Sqibb, Lundbeck A/S, GlaxoSmithKline plc., Novartis AG, Sanofi, Cipla Ltd., Glenmark Life Sciences Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Intas Pharmaceutical Industries Ltd., Mylan N.V., Sumitomo Dainippon Pharma Co. Ltd., and Others. Prominent players operating in the target market are focusing on the strategic partnerships as well as launching of the products in order to gain competitive edge in the target market. For instance, in 2018, Novartis Use Self-Tracking App to determine Prevalence of Anxiety, Depression in Migraine. Digital health company & drug maker Novartis have announced joint research pointing to an increase in anxiety & depression with higher migraine frequency among tens of thousands of patients with migraine in the United States.

Anxiety And Depression Treatment Market Company Profile

  • Novartis AG*
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Pfizer Inc.,
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co. Inc.,
  • AstraZeneca
  • Bristol Myers Sqibb
  • Lundbeck A/S
  • GlaxoSmithKline plc.,
  • Novartis AG
  • Sanofi
  • Cipla Ltd.,
  • Glenmark Lifesciences Limited
  • Lupin Limited
  • Sun Pharmaceutical Industries Ltd.,
  • Intas Pharmaceutical Industries Ltd.,
  • Mylan N.V.,
  • Sumitomo Dainippon Pharma Co. Ltd.

 “*” marked represents similar segmentation in other categories in the respective section

Anxiety And Depression Treatment Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for medical carts Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Product
      • Market Snippet, By Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Anxiety and Depression Treatment Market, By Product
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Antidepressant Drugs
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • SSRIs (Selective Serotonin Reuptake Inhibitor)
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • SNRIs (Serotonin-Norepinephrine Reuptake Drug)
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Benzodiazepine
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Devices
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Therapy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  1. Global Anxiety and Depression Treatment, By Indication, 2020 – 2030, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • MDD (Major Depressive Disorder)
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • OCD (Obsessive-Compulsive Disorder)
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Phobia
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  2. Global Anxiety and Depression Treatment, By Distribution Channel, 2020 – 2030, (US$ Bn)
    • Overview                                      
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospital Pharmacy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Retail Pharmacy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Online Pharmacy
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
  3. Global Anxiety and Depression Treatment, By Region, 2020 – 2030, (US$ Bn)
    • Overview
      • Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Application, 2020 – 2030
      • Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  4. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  5. Company Profiles
  • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Merck & Co. Inc.,
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AstraZeneca
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Bristol-Myers Sqibb
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Lundbeck A/S
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • GlaxoSmithKline plc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Sanofi
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Cipla Ltd.,
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Glenmark Life Sciences Limited
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Lupin Limited
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Sun Pharmaceutical Industries Ltd.,
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Intas Pharmaceutical Industries Ltd.,
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Mylan N.V.,
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • Sumitomo Dainippon Pharma Co. Ltd.,
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The Anxiety and Depression Treatment Market is segmented into basis of on product, indication, distribution channel, and region.

Rise in mental health illness of an individual is one of the leading factors for the anxiety and depression treatment market growth.

By region, The Asia-pacific market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as India and China, and technological advancements.

The Key players operating in the Green Anxiety and Depression Treatment Market includes Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., AstraZeneca, Bristol-Myers Sqibb, Lundbeck A/S, GlaxoSmithKline plc., Novartis AG, Sanofi, Cipla Ltd., Glenmark Life Sciences Limited, Lupin Limited, Sun Pharmaceutical Industries Ltd., Intas Pharmaceutical Industries Ltd., Mylan N.V., Sumitomo Dainippon Pharma Co. Ltd., and Others.